Beyond Air, Inc. $XAIR

What the company doesAI summary of filing

Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company developing nitric oxide (NO) generators and delivery systems. The company's lead product, LungFit® PH, received FDA premarket approval in June 2022 for treating persistent pulmonary hypertension of the newborn (PPHN) and received European CE mark approval in November 2024 for PPHN and peri- and post-operative pulmonary hypertension. Beyond Air generates revenue from the commercial launch of LungFit® PH in the U.S. market beginning in July 2022 and from distribution agreements covering over 40 countries internationally. The company is also developing pipeline candidates including LungFit® PRO for viral lung infections, LungFit® GO for nontuberculous mycobacteria (NTM) infections, and through majority-owned affiliates, programs for solid tumor treatment and neurological conditions. [10-K 2026-06-26]

Segments: LungFit® PH (PPHN and cardiac surgery), LungFit® PRO (viral pneumonia and bronchiolitis), LungFit® GO (NTM lung infection), Ultra-high concentration NO for solid tumors (Beyond Cancer)